Drug Discovery

#Drug discovery

Ebook: The significance of mAbs in drug discovery and development

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. This eBook, sponsored by Evotec, examines the challenges, solutions and successes in mAb discovery and development. Download this exclusive eBook to learn more about: The 2025 scientific… Read More

#DDW eBooks

#Artificial intelligence (AI) #Drug discovery #Events #Webinar

Last chance to register: How is AI innovating in drug discovery?

Hosted by Drug Discovery World and sponsored by Benchling, this free webinar will explore the impact of AI on drug discovery innovation. Taking place on 26 June, the webinar will see AI experts and leaders discuss where innovation is occurring and what the challenges are to overcome in… Read More

Webinar date:
Sponsored by Benchling
#News

#Drug discovery #Financing #Non-animal model (NAM) #Organoids #Parallel Bio

Parallel Bio secures $21m to advance human-first drug discovery

Biotech company Parallel Bio has raised $21 million in a Series A funding led by AIX Ventures.   The round attracted new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.   Robert… Read More

#Business & Investment #News

Researcher in a medical lab
#Contract Research Organisations (CROs) #Drug discovery #In vitro assays #Toxicology

CN Bio introduces cross-species DILI services

CN Bio has introduced two new animal microphysiological system (MPS) models to its contract research services (CRS) that it hopes will enhance translatability in preclinical drug safety and toxicology assessments.  Building upon its drug induced liver injury (DILI) assay, the company says the expanded offering enables rapid,… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #ICON #Public health

ICON on the real-world integration of AI in drug R&D

DDW’s Megan Thomas speaks with ICON’s IT Director, Marco Heldoorn, about leveraging artificial intelligence (AI) to enhance efficiency, decision-making, and patient outcomes across the drug development lifecycle, from early feasibility to post-marketing. MT: Could you provide an overview of your findings when it comes to drug development and AI? TO:… Read More

#Business & Investment #Exclusive Content

Organ-on-a-chip
#Drug discovery #Emulate #High throughput screening #Organ-on-a-chip

Emulate launches unique high-throughput organ-chip platform

Emulate has launched the AVA Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in a single run.   The company says that AVA delivers an unprecedented magnitude of in vivo-level insights faster than animal models while cutting consumable… Read More

#News

Antibodies
#Antibody drug conjugate (ADC) #Antibody-dependent cellular cytotoxicity #Case study #Drug discovery #Flow Cytometry

Case Study: ADC synthesis, development, and characterisation

A new Case Study is now available from Eurofins Discovery entitled ‘Synthesis & characterization of trastuzumab-based ADCs using fluorescent & cytotoxic payloads‘. Delve into these case studies on ADC synthesis, development, and characterisation, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow… Read More

#News

#Antibody drug conjugate (ADC) #Antibody-dependent cellular cytotoxicity #Drug discovery #Flow Cytometry

Synthesis & characterisation of trastuzumab-based ADCs using fluorescent & cytotoxic payloads

Delve into these case studies on ADC synthesis, development, and characterisation, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow cytometry and internalisation assays confirmed antigen targeting and cellular uptake. Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy… Read More

#Resources

AI
#Artificial intelligence (AI) #Drug discovery #Events #Webinar

Webinar: How is AI innovating in drug discovery?

Hosted by Drug Discovery World and sponsored by Benchling, this free webinar will explore the impact of AI on drug discovery innovation. Taking place on 26 June, the webinar will see AI experts and leaders discuss where innovation is occurring and what the challenges are to overcome in… Read More

Webinar date:
Sponsored by Benchling
#News

Chained to fibromyalgia concept
#Chronic pain #Drug discovery #Fibromyalgia #Medicinal cannabis #Painkillers

Where are the new drugs for fibromyalgia?

DDW’s Diana Spencer reviews the latest research into fibromyalgia treatment and the new therapies currently in development.  With no existing cure for fibromyalgia, a chronic pain syndrome, current treatments focus on managing the symptoms like pain, fatigue and poor sleep, with exercise being a key part of… Read More

#Exclusive Content

#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Latest developments in cancer research

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News

#Artificial intelligence (AI) #Drug discovery #Events #Webinar

Webinar: Hear from the AI and drug discovery experts

Hosted by Drug Discovery World and sponsored by Benchling, this free webinar will explore the impact of AI on drug discovery innovation. Taking place on 26 June, the webinar will see AI experts and leaders discuss where innovation is occurring and what the challenges are to overcome in… Read More

Webinar date:
Sponsored by Benchling
#News

#Appointment #Drug discovery #New appointment

Drug discovery’s senior appointments: Q2 2025

Here, we provide an overview of the c-level moves that have taken place within the industry between April and June 2025. The ABPI has confirmed that Russell Abberley is the latest President-elect. Abberley, Vice President and General Manager of Amgen UK and Ireland, formally took up the Presidency on 13… Read More

#News

#Cytiva #Drug development #Nuclera #Proteins

Nuclera and Cytiva team up to accelerate protein production

Biotechnology company Nuclera and life sciences organisation Cytiva have announced a collaboration focused on accelerating the production, purification and characterisation of proteins required for drug research and development. The companies aim to enable this goal through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology. Read More

#News

Mass spectrometry
#Drug discovery #Lab technology #Mass spectrometry / NMR

Cerno unveils mass spec breakthroughs at ASMS Meeting

Cerno will present new data on its universal mass spectrometry software at the American Society of Mass Spectrometry (ASMS) Annual Meeting in Baltimore MD.   The Cerno team will also demonstrate their MassWorks and GC/ID software and meet with conference attendees at booth #121.  “Across a… Read More

#News

Cancer cells
#Cancer research #Drug discovery #Events #Oncology #Webinar

Webinar: Cancer research developments

This free webinar at 3pm BST on 12 June, hosted by DDW and sponsored by Scale Biosciences, will see experts and thought-leaders from the cancer research sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects in the oncology field. … Read More

Webinar date:
Sponsored by Scale Biosciences
#News